Horizon Europe beneficiaries must disseminate their results, but they should assess intellectual property (IP), confidentiality and other legitimate interests before making a disclosure. A public conference abstract, journal article, software repository or press release can reveal information that is difficult—or impossible—to protect afterwards.
The practical solution is not to stop communicating. It is to establish a publication-clearance process that connects researchers, result owners, IP advisers and communication teams. This guide explains the rules, the decisions to make and the evidence to keep.
Can Horizon Europe beneficiaries protect results and still meet dissemination obligations?
Yes. Protection, exploitation, dissemination and communication are complementary obligations and activities, not mutually exclusive choices. Horizon Europe expects beneficiaries to examine whether results should be protected, particularly where commercial or industrial exploitation is reasonably foreseeable. Dissemination must respect legitimate interests, confidentiality and applicable open-science obligations.
For a broader explanation of how these activities connect, see What Is the Difference Between Communication, Dissemination and Exploitation in Horizon Europe?.
These concepts serve different purposes:
| Activity | Main purpose | Example |
|---|---|---|
| Protection | Secure rights or preserve valuable confidentiality | File a patent application or safeguard trade secrets |
| Exploitation | Put results to use | Licence a technology, adopt a method, inform a policy |
| Dissemination | Share project results with audiences able to use them | Publish a paper, release research software |
| Communication | Inform and engage audiences about the project and its activities | Publish a project story or social-media post |
Important distinction: a press release that describes a project is communication, but one that reveals new technical findings may also disclose results. Review the content, not merely the format.
Which Horizon Europe rules govern IP protection and dissemination?
Article 16 and the Horizon Europe-specific provisions of Annex 5 of the Model Grant Agreement address results, ownership, protection and access rights; Article 17 and Annex 5 govern communication, dissemination and open science. The applicable signed Grant Agreement, call conditions and Consortium Agreement should always be checked together.
As a general principle, the beneficiary generating a result owns it. Where two or more beneficiaries jointly generate inseparable results or their contributions cannot be distinguished for protection purposes, joint ownership rules may apply. Ownership does not eliminate other partners' contractual access rights.
Not every result needs a patent or other registered right. Beneficiaries should select protection that is appropriate to the result and its intended use. A result intended for open scientific reuse may be disseminated without patent protection following a documented assessment; valuable know-how may instead need to remain confidential.
How much notice must partners receive before dissemination?
Under the standard Horizon Europe rules, a beneficiary intending to disseminate results must give the other beneficiaries at least 15 days' advance notice, unless otherwise agreed. Other beneficiaries may object within 15 days of receiving that notice, unless otherwise agreed, if they can demonstrate significant harm to their legitimate interests concerning background or results.
An objection is not an automatic permanent veto. The parties should agree appropriate safeguards, such as removing sensitive information or postponing disclosure until a protection filing has been made. Consortium Agreements may set different procedures or longer review periods; apply the rules agreed for your project. The protection decision should also feed into the project's exploitation and dissemination plan.
A reliable workflow is:
- Submit the planned material and intended publication date to the consortium's designated review contact.
- Identify which results and background information it contains, and who owns them.
- Review patentability, confidentiality, personal data, security, third-party rights and exploitation plans.
- Notify beneficiaries according to the applicable notice procedure and preserve evidence of the notification.
- Resolve objections and obtain any required internal approvals.
- Publish the cleared version, with the required EU funding acknowledgement, and archive the final content and approval trail.
Example: a researcher plans to submit an abstract on 30 November. Rather than waiting until mid-November to start the review, the team should first allow time for invention assessment, any patent filing and the contractual notification period. A patent lawyer may need more time than the minimum dissemination-notice period.
Which types of intellectual property can protect project results?
The correct mechanism depends on what the consortium has created and how it plans to exploit it.
| Protection mechanism | Typical project result | Key consideration |
|---|---|---|
| Patent | A qualifying technical invention, process or device | Public disclosure before filing may destroy novelty in many jurisdictions |
| Copyright | Original software code, reports, illustrations or training material | Usually arises automatically; registration is generally not required in the EU |
| Trade secret | Confidential formula, process, dataset-related know-how | Requires appropriate secrecy measures; public disclosure defeats secrecy |
| Trademark | Name or distinctive sign for a service or spin-off | Protects brand identification, not the underlying technology |
| Registered design | Eligible product appearance or visual design | Filing and novelty rules depend on the jurisdiction |
| Database rights | Certain original database structures or qualifying database investments | Protection does not automatically cover every individual data point |
A computer-implemented invention may be patentable in certain circumstances, but an algorithm is not automatically patentable simply because it is novel. Likewise, releasing code under an open-source licence does not mean abandoning copyright: it grants permissions under specified terms.
For high-value results, seek specialist advice on patentability, freedom to operate, territorial coverage and filing costs.
What should be checked before a paper, presentation or press release goes public?
Review the exact information to be disclosed and the possible consequences of making it public. Use this pre-publication checklist:
- Have the potentially exploitable results and their owners been identified?
- Has an IP or technology-transfer contact assessed whether protection is justified?
- Have the relevant partners been notified under the agreed procedure?
- Have any objections been resolved and documented?
- Does the content reveal confidential background, unpublished inventions or trade secrets?
- Are third-party materials, licences, permissions and attribution requirements respected?
- Are personal data, research-participant information and security-sensitive details handled lawfully?
- Does the final material comply with the Grant Agreement's communication and acknowledgement requirements?
- Is the approved version archived with the decision record?
A simple results register should capture the result identifier, description, owner(s), originating work package, protection decision, intended exploitation, planned disclosure and clearance status.
How should a consortium handle common disclosure scenarios?
The same review principles apply to different publication channels, but the practical risks differ.
| Scenario | Main risk | Sensible action |
|---|---|---|
| Conference abstract | Technical disclosure before a patent filing | Review the abstract before submission, not only before the event |
| Scientific paper | Publication of enabling details | Coordinate protection decisions and open-access requirements early |
| Public GitHub repository | Irreversible release of code, secrets or third-party material | Audit code and dependencies; select an appropriate licence |
| Press release | Overly specific description of an unprotected invention | Explain the challenge and benefits without disclosing protected details |
| Public deliverable | Exposure of confidential know-how or personal data | Review content and agreed dissemination level; request a formal change where needed |
| Demonstration or trade fair | Public display of a novel technical feature | Check whether the demonstration itself constitutes a disclosure |
A public deliverable cannot simply be converted into a confidential deliverable by attaching an internal annex. Its formal dissemination level and reporting requirements must be respected. Where necessary, discuss an amendment or other authorised handling with the project officer before the disclosure deadline.
Who owns results generated by multiple Horizon Europe partners?
Ownership generally follows the generation of results, while joint ownership arises in defined circumstances. The Consortium Agreement should explain how partners identify ownership, manage joint results, share protection costs, grant access rights and resolve disagreements.
For a jointly developed sensor, for example, the consortium should not assume that every partner automatically owns an equal share. It should document each contribution, apply the relevant joint-ownership rules and agree who may file, license or exploit the result.
Three terms should not be confused:
- Background: pre-existing data, know-how or information needed for the action or exploitation, subject to agreed access rights.
- Results: outputs generated by the action, whether or not they can be protected.
- Access rights: contractual rights allowing beneficiaries to use background or results for specified purposes and under specified conditions.
The ownership register and the project's results reporting should remain consistent. Where applicable, beneficiaries must also complete the Results Ownership List as part of reporting.
Does open science prevent patenting or commercial exploitation?
No. Open science and IP protection can coexist, but timing and licensing choices matter. Filing a patent before publication may preserve a route to commercial exploitation while allowing later disclosure. Open-source software can support adoption and commercial business models. Open-access publication does not, by itself, extinguish copyright.
Horizon Europe's open-access obligations for peer-reviewed scientific publications and its research-data management requirements must be followed. Research data are managed under the principle “as open as possible, as closed as necessary”, subject to legitimate restrictions such as personal-data protection, confidentiality and exploitation interests.
Do not assume that all data must be made public or that a generic Creative Commons licence is suitable for software. Choose licences that fit the type of output, ownership and intended reuse.
How can communication teams discuss innovations before protection is complete?
Communicate the problem, the people, the research approach and the expected benefits without disclosing sensitive enabling details. A communication team can often prepare public-facing material while an IP decision is pending. Grant 360's complete guide to Horizon Europe communication explains how to organise the wider communication workflow.
For example, instead of publishing a detailed schematic of a novel water-treatment membrane, the project could explain the water-quality challenge, show non-sensitive pilot-site images and describe the performance questions researchers are investigating. Avoid unverified claims about performance or patent status.
A phrase such as “patent pending” should be used only where a relevant application has actually been filed. Communication agencies, designers and videographers should receive only the materials they need, under suitable confidentiality and rights arrangements. Outsourcing content production does not transfer the beneficiary's Grant Agreement obligations.
How can IP review become part of routine project management?
Build the review into existing work-package, deliverable and communication processes rather than treating it as an emergency approval before publication. A proportionate system can work even in a small consortium:
- At project start: assign an IP contact, identify relevant background and agree review responsibilities.
- At regular technical meetings: record new results, potential owners and possible exploitation routes.
- Before every planned disclosure: perform an IP/confidentiality check and follow the contractual notification process.
- At reporting milestones: update the results register, exploitation and dissemination plan, and ownership information.
- Before project closure: agree follow-up responsibilities for filings, licences, maintenance fees and exploitation.
Use a shared tracker with fields such as draft → under IP review → partner notification → cleared → published. Restrict access to sensitive documents and maintain version history. Review security, access control and data-protection measures based on actual risks; encryption alone does not establish GDPR compliance.
Where can Horizon Europe beneficiaries obtain IP support?
Start with the European Commission's official guidance and specialised support services. The European IP Helpdesk offers first-line IP guidance for EU-funded research. National patent offices and institutional technology-transfer offices can provide further support; qualified legal professionals are appropriate for filing and disputes.
The Commission also offers dissemination and exploitation support, including the Booster service. Availability and names of individual programmes may change, so check the current official pages rather than relying on old project templates.
Frequently asked questions
Can we publish a scientific paper before filing a patent?
You can, but public disclosure may compromise patent novelty. Have the invention assessed and, if protection is justified, coordinate filing before public release. Check the applicable notice rules as well.
Is the 15-day notification rule always mandatory?
It is the standard Horizon Europe rule unless otherwise agreed. Check your signed Grant Agreement and Consortium Agreement for the applicable procedure, notice period and objection deadline.
Can a consortium partner stop another partner's publication?
A partner may object under the applicable rules where it can show significant harm to its legitimate interests in background or results. The parties should identify proportionate safeguards; an objection is not an unrestricted right to block all publication.
Does every Horizon Europe result need a patent?
No. Protection should be assessed according to commercial or industrial potential, legal feasibility and intended exploitation. Copyright, trade secrets, open licensing or dissemination without registered protection may be more appropriate.
Can confidential research data remain closed under Horizon Europe?
Yes, where justified by legitimate interests or legal obligations. Data management must still comply with the applicable Grant Agreement, data management plan and relevant law.
Who should approve a project's social-media post?
The consortium should define an internal approval process. Posts revealing new results or sensitive information need appropriate technical and IP review, even if they are presented as routine communication. The same review should cover the visibility, communication and dissemination obligations applicable to the project.
Conclusion: Protect before disclosure, then share with purpose
Horizon Europe does not require beneficiaries to choose between protecting results and creating impact. It requires them to make informed decisions about ownership, protection, exploitation and dissemination. The most effective safeguard is a documented, repeatable clearance process that begins well before publication.
When researchers, IP specialists and communication teams work from the same results register and publication calendar, a consortium can share valuable knowledge while respecting the rights and legitimate interests that make further exploitation possible.
Official sources and further reading
- European Commission — Annotated Grant Agreement (AGA), version 2.0, April 2025 — see Articles 16–17 and Horizon Europe provisions in Annex 5.
- European IP Helpdesk — Frequently asked questions — IP ownership, protection, open science and dissemination.
- European Commission — Dissemination and exploitation of research results — policy guidance and current support services.
- European Research Executive Agency — Open science — open-access and open-science resources.
Editorial note: This article summarises standard Horizon Europe provisions and is not legal advice. Always check the signed Grant Agreement, applicable call conditions and Consortium Agreement before making a disclosure or IP decision.